Unibest

Pharmaceutical intermediates

Bedaquiline Fumarate Intermediates

3 pharmaceutical intermediates for Bedaquiline Fumarate. Indication: Multidrug-resistant tuberculosis.

提交项目All intermediates

About Bedaquiline Fumarate

Originator
Janssen Therapeutics Div Janssen Products Lp
Indication
Multidrug-resistant tuberculosis
Approved Date
12/28/2012
DS/DP
12/01/2016

Available intermediates

3 intermediates currently listed for Bedaquiline Fumarate. Request specifications, documentation or a quotation for any item below.

Bedaquiline Fumarate intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
3-Dimethylamino-1-(naphthalen-1-yl)propan-1-one hydrochloride5409-58-5//
3-Benzyl-6-bromo-2-methoxyquinoline654655-69-3//
4-hydroxydinaphtho[2,1 -d:1',2'-f][1,3,2]dioxaphosphepine 4-oxide compound with (1R,2S)-1-(6-bromo-2-methoxyquinolin -3-yl)-4- (dimethylamino)-2-(naphthalen-1-yl)-1-phenylbutan-2-ol(1:1)916329-20-9//

Other programs under B

Baloxavir MarboxilBaricitinibBDTX-1535Belumosudil mesylateBelzutifanBempedoic acidBeraprost SodiumBictegravir

Building toward Bedaquiline Fumarate?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →